Clinical Trial Update: Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years [Phase 4]

View source ↗

Summary

Pfizer-sponsored Phase 4 study evaluated how long antibodies persist after FSME-IMMUN vaccination and the booster response in adults aged 18 to 67; the trial is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tick-borne Encephalitis

Drugs mentioned

• FSME-IMMUN (Tick-borne encephalitis vaccine (inactivated))

Snippet

Sponsor: Pfizer | Conditions: Tick-borne Encephalitis | Phase 4 | Status: COMPLETED